<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487926</url>
  </required_header>
  <id_info>
    <org_study_id>102-2016</org_study_id>
    <nct_id>NCT03487926</nct_id>
  </id_info>
  <brief_title>Microglial Activation in Inflammatory Bowel Disease</brief_title>
  <official_title>Naturalistic Monitoring of Microglial Activation in Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor microglial activation in participants with
      inflammatory bowel disease (IBD) and investigate the relationship that exists between these
      patients and their risk of acquiring major depressive episodes (MDE). Patients with both IBD
      and MDE will be subsequently approached to participate in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:

      Participants may undergo up to 3 PET Scans : [18F]FEPPA PET (for TSPO) before and 3 to 6
      months later and [11C]SL25.1188 PET (for MAO-B) as well as 1 MRI scan.

      The primary hypothesis is that :

        1. The neuroinflammation (TSPO VT) will be increased in PFC, ACC, and insula regions in
           those with inflammatory bowel disease (IBD) patients compared to healthy people.

        2. The neuroinflammation (TSPO VT) in PFC, ACC, and insula regions will be reduced after
           treatment for IBD.

      The Secondary Hypothesis:

        1. Elevations in neuroinflammation (TSPO VT) will be similar in those with ulcerative
           colitis and Crohn's disease.

        2. Neuroinflammation (TSPO VT) will be greater in IBD with depression than in depression
           without IBD.

        3. Biologics (TNFalpha antibody treatments), and fecal transplantation will be associated
           with greater reduction in neuroinflammation in brain than
           Sulfasalazine/5-Aminosalicylates.

        4. MAO-B VT will be elevated in in the PFC, ACC, and insula in IBD compared to healthy
           controls.

      There will be no alterations to standard care of patients due to participation in the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TSPO VT in prefrontal cortex, anterior cingulate cortex, and insula</measure>
    <time_frame>within 3 to 4 weeks after initiation of screening</time_frame>
    <description>Between group comparison for 3 regions in IBD compared to controls (analysis done concurrently for group effect across 3 regions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in TSPO VT in prefrontal cortex, anterior cingulate cortex, and insula before and after 3 to 6 months</measure>
    <time_frame>3 to 6 months</time_frame>
    <description>Change in TSPO VT for three regions (same units for each region)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAO-B VT in prefrontal cortex, anterior cingulate cortex, insula in IBD compared to controls</measure>
    <time_frame>within 3 to 4 weeks after initiation of screening</time_frame>
    <description>Between group comparison for 3 regions in IBD compared to controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between Crohns disease and ulcerative colitis</measure>
    <time_frame>within 3 to 4 weeks of initiating screening of subjects</time_frame>
    <description>comparison of TSPO VT in 3 regions between two types of inflammatory bowel disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between IBD with MDE compared to MDE controls</measure>
    <time_frame>within 3 to 4 weeks after initiation of screening</time_frame>
    <description>Between group comparison for 3 regions in IBD compared to controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between naturalistic treatment with sulfasalazine/5-aminosalicylates versus other interventions like biologics or fecal transplantation</measure>
    <time_frame>3 to 6 months</time_frame>
    <description>differential change in TSPO VT across 3 regions before and after 6 months in those receiving naturalistic treatment with sulfasalazine/5-aminosalicylates versus other naturalistic treatments of fecal transplantation or biologics</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Major Depressive Episode</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1 (IBD primary diagnosis)</arm_group_label>
    <description>Participants have active IBD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2( IBD + comorbid MDE)</arm_group_label>
    <description>1 [18F]FEPPA PET scan in those with IBD symptoms in the past 2 years as well present with MDE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3-Controls</arm_group_label>
    <description>Matched for Level of Depressive Symptoms and Otherwise Healthy
-Subjects in an otherwise healthy state with major depressive episodes, obsessive compulsive disorder, or generalized anxiety disorder will provide psychiatric diagnosis matched controls to those with IBD. Data for group three will be largely obtained from previous recent studies (it is anticipated that 95% of this data is already available).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]FEPPA</intervention_name>
    <description>up to 3 PET Scans ([18F]FEPPA PET scans done 3 to 6 months apart, and one [11C]SL2511.88 PET scan) and 1 MRI</description>
    <arm_group_label>Group 1 (IBD primary diagnosis)</arm_group_label>
    <arm_group_label>Group 2( IBD + comorbid MDE)</arm_group_label>
    <arm_group_label>Group 3-Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma and serum samples will be kept for analysis of genotype, peripheral
      inflammatory markers and protein binding.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community and tertiary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65

          -  aside from IBD groups, otherwise good physical health with no current active medical
             conditions.

        Exclusion Criteria:

          -  no history of neurological illness

          -  no personality disorders (screened with Structured Clinical Interview for DSM V122)

          -  no use of biologics, glucocorticoid antagonists or lithium or medications that bind
             with moderate or higher affinity to benzodiazepine receptors (&lt;500nM) in the previous
             two months

          -  no use of herbal remedies in the previous month that would be expected to influence
             neuroinflammation

          -  non-cigarette smoking

          -  no history of substance abuse and negative urine drug screens for substances of abuse
             including cotinine (urine drug screen is done at screening and on each PET scan day)

          -  no history of psychotic symptoms

          -  not pregnant based on a negative pregnancy test (for women)

          -  not breastfeeding (for women)

          -  no recent treatment with electroconvulsive therapy or magnetic seizure therapy in the
             previous 6 months

          -  No coagulation disorders, or anticoagulant medication use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey H Meyer, M.D.,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Imaging Centre, Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Xu</last_name>
    <phone>4165358501</phone>
    <phone_ext>33677</phone_ext>
    <email>cynthia.xu@camhpet.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S, Meyer JH. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015 Mar;72(3):268-75. doi: 10.1001/jamapsychiatry.2014.2427.</citation>
    <PMID>25629589</PMID>
  </results_reference>
  <results_reference>
    <citation>Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, Xu C, Richter MA, Kahn A, Kish SJ, Houle S, Ravindran L, Meyer JH. Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. JAMA Psychiatry. 2017 Aug 1;74(8):833-840. doi: 10.1001/jamapsychiatry.2017.1567.</citation>
    <PMID>28636705</PMID>
  </results_reference>
  <results_reference>
    <citation>Holmes SE, Hinz R, Conen S, Gregory CJ, Matthews JC, Anton-Rodriguez JM, Gerhard A, Talbot PS. Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. Biol Psychiatry. 2018 Jan 1;83(1):61-69. doi: 10.1016/j.biopsych.2017.08.005. Epub 2017 Aug 12.</citation>
    <PMID>28939116</PMID>
  </results_reference>
  <results_reference>
    <citation>Li H, Sagar AP, KÃ©ri S. Translocator protein (18kDa TSPO) binding, a marker of microglia, is reduced in major depression during cognitive-behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Apr 20;83:1-7. doi: 10.1016/j.pnpbp.2017.12.011. Epub 2017 Dec 19.</citation>
    <PMID>29269262</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Jeff Meyer</investigator_full_name>
    <investigator_title>Program Head, Neurochemical Imaging for Mood Disorders</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

